Kristen Kluska (Cantor Fitzgerald) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Kristen Kluska's stock ratings?

About 41% of Kristen's ratings were profitable over a one-year hold, with an average return of -9.2% per rating, measured by 13Foresight from historical prices.

Q: How is Kristen ranked?

Kristen Kluska is ranked #2474 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Kristen Kluska

CANT

Kristen Kluska

Cantor Fitzgerald

Wall Street Analyst

★☆☆☆☆

#2474

on 13Foresight · ranked by our own returns

41%

Success Rate

-7.2%

Average Return

17 of 41 calls profitable · -23.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 41% of Kristen Kluska's ratings turned a profit when each position was held for 2 year — averaging -7.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

124 Buy 19 Hold 0 Sell

Kristen's Stock Coverage 46 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return
QURE uniQure	Jun 17, 2026	BUY	Strong Buy +16.1% avg upside 29 analysts	—	·
CDXS Codexis	Jun 16, 2026	BUY	Strong Buy +291.5% avg upside 13 analysts	$11.00 327.93% Upside	·
CLDX Celldex	Jun 14, 2026	BUY	Strong Buy +20.6% avg upside 28 analysts	$67.00 106.59% Upside	+0.8%
ZVRA Zevra Therapeutics	Jun 08, 2026	BUY	Strong Buy +85.3% avg upside 15 analysts	$34.00 163.50% Upside	+4.3%
RARE Ultragenyx Pharmaceutical	May 20, 2026	BUY	Strong Buy +142.1% avg upside 36 analysts	$96.00 249.82% Upside	·
MNPR Monopar Therapeutics Inc	May 14, 2026	BUY	Strong Buy +45.9% avg upside 18 analysts	$109.00 61.53% Upside	-2.8%
CAPR Capricor Therapeutics	May 12, 2026	BUY	Strong Buy +68.2% avg upside 12 analysts	$62.00 118.43% Upside	-8.7%
IRON Disc Medicine	May 12, 2026	BUY	Strong Buy +20.2% avg upside 21 analysts	$125.00 76.51% Upside	+2.3%
MREO Mereo Biopharma Group Plc	May 12, 2026	BUY	Strong Buy +1152.4% avg upside 11 analysts	$3.00 869.56% Upside	-4.0%
SLDB Solid Biosciences	May 12, 2026	BUY	Strong Buy +90.3% avg upside 23 analysts	$16.00 92.18% Upside	-10.4%
ESPR Esperion	May 01, 2026	HOLD	Buy +701.2% avg upside 22 analysts	$3.16 0.25% Upside	+1.3%
DBVT DBV Technologies SA - American	Apr 30, 2026	BUY	Strong Buy +55.4% avg upside 15 analysts	$48.00 209.01% Upside	-22.5%
RNAC Cartesian Therapeutics	Apr 30, 2026	BUY	Strong Buy +228.2% avg upside 19 analysts	$16.00 66.09% Upside	+43.2%
PTCT PTC Therapeutics	Apr 28, 2026	BUY	Buy -1.5% avg upside 29 analysts	$124.00 57.09% Upside	+11.8%
TSE:EPRX Eupraxia Pharmaceuticals	Mar 31, 2026	BUY	Strong Buy +147.7% avg upside 8 analysts	$26.87 196.60% Upside	·
LXEO Lexeo Therapeutics, Inc.	Mar 30, 2026	BUY	Strong Buy +313.8% avg upside 11 analysts	$19.00 285.45% Upside	-3.4%
ADMA ADMA Biologics	Mar 25, 2026	HOLD	Strong Buy +57.2% avg upside 15 analysts	$30.00 260.93% Upside	-12.6%
TSHA Taysha Gene Therapies	Mar 24, 2026	BUY	Strong Buy +102.5% avg upside 21 analysts	$19.00 195.89% Upside	+49.9%
FULC Fulcrum Therapeutics	Mar 19, 2026	BUY	Hold +138.4% avg upside 13 analysts	$24.00 548.74% Upside	-5.0%
SRPT Sarepta Therapeutics	Mar 16, 2026	HOLD	Buy +244.5% avg upside 49 analysts	$21.00 19.80% Upside	-5.5%
SKYE Skye Bioscience	Mar 10, 2026	HOLD	Strong Buy +1354.2% avg upside 9 analysts	$2.00 182.79% Upside	+1.4%
RIGL Rigel	Mar 03, 2026	HOLD	Strong Buy -27.5% avg upside 17 analysts	$38.00 15.53% Upside	-0.9%
AQST Aquestive Therapeutics	Mar 02, 2026	BUY	Strong Buy +88.9% avg upside 10 analysts	$11.00 133.49% Upside	+2.3%
SUPN Supernus Pharmaceuticals	Feb 24, 2026	BUY	Strong Buy +21.7% avg upside 7 analysts	$63.00 42.04% Upside	-7.3%
ABEO Abeona Therapeutics	Feb 23, 2026	BUY	Strong Buy +195.8% avg upside 17 analysts	$28.00 385.28% Upside	+5.2%
PHAT Phathom Pharmaceuticals	Jan 13, 2026	BUY	Strong Buy +163.8% avg upside 14 analysts	$29.00 166.58% Upside	-30.4%
XFOR X4 Pharmaceuticals	Nov 21, 2025	BUY	Strong Buy +491.4% avg upside 15 analysts	$14.00 231.84% Upside	+8.8%
HUMA Humacyte	Jul 01, 2024	BUY	Strong Buy +665.4% avg upside 11 analysts	$7.00 657.29% Upside	-80.3%
IRD Opus Genetics	May 13, 2024	BUY	Strong Buy +154.5% avg upside 23 analysts	—	+319.2%
LCTX Lineage Therap	Feb 04, 2024	BUY	Strong Buy +342.7% avg upside 16 analysts	$6.00 395.90% Upside	+67.3%
OTLK Outlook Therapeutics	Aug 30, 2023	HOLD	Buy +484.7% avg upside 11 analysts	$20.00 1165.87% Upside	-84.2%
DRTS Alpha Tau Medical Ltd	Aug 28, 2023	BUY	Strong Buy +41.1% avg upside 5 analysts	$23.00 135.16% Upside	+3.4%
ATNM Actinium Pharmaceuticals	Jun 28, 2023	BUY	Strong Buy +633.5% avg upside 11 analysts	$27.00 2521.36% Upside	-80.7%
DMRA Damora Therapeutics	Jun 26, 2023	BUY	Strong Buy +28.3% avg upside 19 analysts	$17.00 19.97% Downside	·
CMMB Chemomab Therapeutics	Jun 09, 2023	HOLD	Strong Buy +1689.5% avg upside 6 analysts	—	-24.6%
HEPA Hepion Pharmaceuticals	May 15, 2023	BUY	Strong Buy +82042.8% avg upside 9 analysts	$28.00 46566.65% Upside	·
EVLO Evelo Biosciences	Mar 16, 2023	HOLD	Buy +4499999900.0% avg upside 5 analysts	$20.00 1999999899.94% Upside	·
HTGMQ HTG Molecular Diagnostics	Mar 10, 2023	HOLD	Buy +7333233.3% avg upside 6 analysts	—	·
PHGE BiomX	Mar 10, 2023	HOLD	Buy +4708.6% avg upside 4 analysts	—	-82.4%
IBIO Ibio	Dec 21, 2022	HOLD	Strong Buy +244.7% avg upside 11 analysts	$10.00 491.76% Upside	-72.4%
GLMD Galmed Pharmaceuticals	Aug 04, 2022	HOLD	Buy +4113.3% avg upside 13 analysts	$10.50 1710.28% Upside	-95.5%
ERNA Eterna Therapeutics	Dec 29, 2021	BUY	Strong Buy +1061.3% avg upside 4 analysts	$180.00 2803.14% Upside	-97.9%
OCGN Ocugen	Sep 28, 2021	HOLD	Strong Buy +645.9% avg upside 17 analysts	$4.00 222.51% Upside	-94.3%
MBIO Mustang Bio	May 12, 2021	BUY	Strong Buy +938.4% avg upside 5 analysts	$10.00 1438.44% Upside	-89.2%
SCPX Scorpius Holdings	Mar 02, 2021	BUY	Strong Buy +1664672.8% avg upside 11 analysts	$22.00 1999900.05% Upside	·
EVGN Evogene	Nov 30, 2020	BUY	Strong Buy +1967.8% avg upside 6 analysts	$9.00 1613.93% Upside	-81.8%

🔒 41 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Kristen Kluska — Frequently Asked Questions

How accurate are Kristen Kluska's stock ratings?

Based on the calls 13Foresight could measure, about 41% of Kristen's ratings were profitable over a one-year hold, with an average return of -9.2% per rating, or -19.2% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Kristen ranked on 13Foresight?

Kristen Kluska is currently ranked #2474 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Kristen cover?

Kristen most recently has ratings on QURE, CDXS, CLDX, ZVRA, RARE, MNPR, CAPR, IRON, MREO, SLDB, ESPR, DBVT and 34 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!